We are live on ! Find out more
CV

Clarus Ventures Portfolio holdings

AUM $425M
1-Year Est. Return 26.13%
This Fund
S&P 500
This Quarter Est. Return
+17.94%
1 Year Est. Return
+26.13%
3 Year Est. Return
+70.29%
5 Year Est. Return
+162.11%
10 Year Est. Return
–
AUM
$350M
AUM Growth
+$99.7M
Cap. Flow
+$52.3M
Cap. Flow %
14.92%
Top 10 Hldgs %
100%
Holding
8
New
2
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
SIEN
Sientra, Inc.
SIEN
+$46.6M
2
EVFM
Evofem Biosciences, Inc. Common Stock
EVFM
+$8.99M

Top Sells

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$3.31M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$97.4M 27.82%
3,338,067
-130,428
-4% -$3.31M
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$69.8M 19.92%
1,554,744
– –
NSTG
3
DELISTED
NanoString Technologies, Inc.
NSTG
$55.2M 15.75%
3,959,440
– –
SIEN
4
DELISTED
Sientra, Inc.
SIEN
$45.8M 13.09%
+273,077
New +$46.6M
OXFD
5
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$35.1M 10.03%
2,579,062
– –
TLOG
6
DELISTED
TetraLogic Pharmaceuticals Corporation
TLOG
$22.4M 6.39%
4,644,705
– –
VBIV
7
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$16.6M 4.73%
165,703
– –
EVFM
8
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$8.01M 2.29%
+11,905
New +$8.99M

Similar funds

LLC
Latimer Light Capital New York $432M AUM 25.5% 1-Year Est. Return
VIA
Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return
SPC
Salient Private Client Houston, Texas $513M AUM 10.97% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
CG
Clinton Group New York $279M AUM 4.76% 1-Year Est. Return
AAM
Amerigo Asset Management George Town, Cayman Islands $254M AUM 115.73% 1-Year Est. Return
SE
Summit Equities Parsippany, New Jersey $601M AUM 9.74% 1-Year Est. Return
CA
Cynosure Advisors Salt Lake City, Utah $238M AUM 4% 1-Year Est. Return

Clarus Ventures's Q4 2014 Portfolio in Review

As of Q4 2014, Clarus Ventures held 8 positions worth $350M, up 40% from $251M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Clarus Ventures deployed $52.3M of net new capital in Q4 2014, opening 2 new positions. Its largest new stake was Sientra, Inc.: 273,077 shares worth $45.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Aerie Pharmaceuticals, an estimated $3.31M trimmed.

  • Clarus Ventures's largest Q4 2014 buy was Sientra, Inc.: 273,077 shares worth $45.8M.
  • Clarus Ventures's biggest Q4 2014 reduction was Aerie Pharmaceuticals, cutting an estimated $3.31M.
  • Clarus Ventures's ten largest holdings make up 100% of its $350M portfolio in Q4 2014.
  • Clarus Ventures opened 2 new positions and closed 0 in Q4 2014.
  • Clarus Ventures's portfolio value rose 40% quarter-over-quarter to $350M.

Based on Clarus Ventures's 13F filing for Q4 2014, filed 12 Feb 2015.